Document is current
Any future updates will be listed below
-
Authors
Greenwald, Noah F. https://orcid.org/0000-0002-7836-4379
Nederlof, Iris https://orcid.org/0000-0001-7608-6515
Sowers, Cameron
Ding, Daisy Yi
Park, Seongyeol https://orcid.org/0000-0002-9236-5853
Kong, Alex
Houlahan, Kathleen E. https://orcid.org/0000-0002-2273-2099
Varra, Sricharan Reddy https://orcid.org/0009-0000-5757-6818
de Graaf, Manon
Geurts, Veerle
Liu, Candace C.
Ranek, Jolene S. https://orcid.org/0000-0002-0701-0565
Voorwerk, Leonie
de Maaker, Michiel
Kagel, Adam
McCaffrey, Erin
Khan, Aziz https://orcid.org/0000-0002-6459-6224
Yeh, Christine Yiwen https://orcid.org/0000-0003-4217-8555
Fullaway, Christine Camacho https://orcid.org/0000-0002-4924-591X
Khair, Zumana
Simon, Brennan G. https://orcid.org/0000-0002-7255-2766
Bai, Yunhao
Piyadasa, Hadeesha
Risom, Tyler
Delmastro, Alea https://orcid.org/0000-0002-7959-3165
Hartmann, Felix J. https://orcid.org/0000-0002-4174-2276
Mangiante, Lise https://orcid.org/0000-0001-8309-0950
Sotomayor-Vivas, Cristina https://orcid.org/0000-0001-8228-477X
Bendall, Sean C. https://orcid.org/0000-0003-1341-2453
Schumacher, Ton N. https://orcid.org/0000-0003-0517-8804
Ma, Zhicheng
Bosse, Marc https://orcid.org/0000-0003-4912-8059
van de Vijver, Marc J.
Tibshirani, Robert
Horlings, Hugo M. https://orcid.org/0000-0003-4782-8828
Curtis, Christina https://orcid.org/0000-0003-0166-3802
Kok, Marleen https://orcid.org/0000-0001-9043-9815
Angelo, Michael https://orcid.org/0000-0003-1531-5067
- License Information
-
More Information
Article History
Received: 3 April 2025
Accepted: 7 January 2026
First Online: 18 February 2026
Competing interests
: N.F.G. is an advisor for Cellformatica. T.N.S. is advisor for Allogene Therapeutics, Asher Bio, Merus, Neogene Therapeutics and Scenic Biotech, is a stockholder in Allogene Therapeutics, Asher Bio, Cell Control, Celsius, Merus and Scenic Biotech and is venture partner at Third Rock Ventures, all outside of the current work. M.K. reports research funding to the institute from BMS, Roche and AstraZeneca/MedImmune and an advisory role/speakers fee (all compensated to the institute) for Alderaan, BMS, Domain Therapeutics, Medscape, Roche, MSD and Daiichi Sankyo, outside the submitted work. M.A. is a named inventor on patent US20150287578A1, which covers the mass spectrometry approach used by MIBI to detect elemental reporters in tissue using secondary-ion mass spectrometry. M.A. is a board member and shareholder in IonPath, which develops and manufactures the commercial MIBI platform. The other authors declare no competing interests.
